Featured Story | By Ben Adams After seven years running Merck’s R&D engine, much of which has revolved around cancer blockbuster Keytruda and, now, COVID-19 vaccines, Roger Perlmutter, M.D., Ph.D., is hitting the exit. read more |
| |
|---|
|
Top Stories By Nick Paul Taylor The FDA has issued a complete response letter to Mesoblast’s request for approval of allogeneic cell therapy remestemcel-L in children with steroid-resistant graft-versus-host disease. FDA officials want to see data from at least one additional clinical trial before granting full authorization, but Mesoblast is still hoping to snag an accelerated approval using its existing data. read more By Ben Adams Nearly two months after GlaxoSmithKline’s vaccine head left the Big Pharma in the middle of it making a pandemic shot, Jack Bailey has penned a deal to lead cancer biotech G1 Therapeutics. read more By Nick Paul Taylor The FDA has lifted the clinical hold on a phase 1/2 clinical trial of Solid Biosciences’ gene therapy treatment for Duchenne muscular dystrophy. Solid Bio secured clearance to resume dosing in the trial after making manufacturing changes to cut the number of viral particles given to patients. read more By Amirah Al Idrus Synthetic Biologics and Cedars-Sinai Medical Center are pulling the plug on a phase 2b study in irritable bowel syndrome because it’s unlikely to hit its primary objective. Cedars-Sinai, the sponsor, will do a “comprehensive review” of the data and publish the findings. read more By Amirah Al Idrus As Corvidia CEO, Marc de Garidel saw the heart disease biotech through a $2.1 billion acquisition by Novo Nordisk. Barely two months later, he’s back in the saddle, this time at AZTherapies, a company working on treatments for Alzheimer’s and other neurodegenerative diseases. read more By Conor Hale By swishing and gargling a small amount of solution for 30 seconds and then spitting it into a funnel and vial, the test both eliminates the need for a nasal swab and assists people who may have trouble in providing sufficient saliva for a direct test. read more By Fraiser Kansteiner Sixfold Bioscience snared an Innovate UK Smart Grant to run early tests on its targeted cancer drug delivery system. Set to run for 18 months, the project will yield a preclinical data pack to help Sixfold hustle its platform into the clinic, potentially by early 2022. read more By Angus Liu Pfizer injected $200 million into CStone Pharmaceuticals for exclusive local commercial rights to the Chinese biotech's PD-L1 agent. After an FDA rejection, Gilead's rheumatoid arthritis med filgotinib won a nod in Japan. Takeda and Ovid shared mixed data for a rare epilepsy med. And more. read more By Kyle Blankenship Merck KGaA names Garijo to top spot; Vico Therapeutics adds Bayer vet Sandbrink as CMO; TriSalus appoints Katz to chief medical role. read more Resources Sponsored by: LabVantage Want to leapfrog lengthy LIMS deployments and position your pharmaceutical lab for success? Find out how with LabVantage Solutions. Sponsored by: Blue Matter Consulting Senior executives from 16 biopharma companies share their thoughts on how COVID-19 will change how the industry engages with its customers. Sponsored by: Evidation Health Achieving patient centricity depends on evolving how evidence is generated. Sponsored by: Outer Edge Technology Cybercriminals Are Actively Exploiting The Coronavirus Pandemic To Gain Entry To Enterprise Networks. Don’t Let Your Company Become The Next Ransomware Headline -- Make These Changes Now! Sponsored by: 4G Clinical This white paper addresses the complexity of basket and umbrella designs, and how modern technology is critical to run flexible, agile and quality-driven trials. Sponsored by: EVERSANA How independent drug launch and commercialization can lead to higher market capitalization. Sponsored by: AMRI Download our white paper to learn more about the growth trends, complex anatomy and intricacies of developing these armed antibodies, as well as AMRI’s approach to their discovery and development. Sponsored by: LexisNexis Risk Solutions Avoid severe compliance penalties by staying on top of evolving laws. Sponsored by: Quotient Sciences This white paper will discuss four principal CMC challenges for the developers of orphan drugs, and the potential solutions which are emerging. Download now >> Sponsored by: Clarify Health In 2020, QED Therapeutics launched first-in-class infigratinib for cholangiocarcinoma (CCA). Learn how the launch team precisely identified and characterized eligible patients by taking an evidence-based approach to its commercial strategy. Sponsored by: Benchling Life science R&D generates a LOT of data. Learn how to make sense of it and harness its potential with this step-by-step guide. Sponsored by: Thermo Fisher Scientific Don’t oversimplify your solubility challenges. Sponsored by: Clinical Ink Download this free whitepaper to learn how to execute fast, high-quality clinical trials through eSource for studies that boost efficiency for both sponsors and sites. Sponsored by: PRA Health Sciences Drug developers and stakeholders must find ways to collaborate, rather than compete, as the RACE Act prompts the need for more pediatric research. Sponsored by: Catalent Get insights on key considerations for a successful tech transfer process for manufacturing a biologic drug product, including a case study on overcoming challenges in a process transfer for a sterile diluent. Sponsored by: Thermo Fisher Scientific Download the whitepaper to learn more. Sponsored by: LexisNexis Risk Solutions Traditionally, pharma companies use a combination of prescription data & internal sales reports to look for potential buyers. Such practice provides only a LIMITED VIEW without competitor information. Download the whitepaper by Optum to see how novel data platforms can uncover hidden insights on medication adherence helping life sciences companies maximize product utilization. Sponsored by: Catalent Pharmaceutical and biotech companies are spending years developing drugs or promising new biologics, all with the hopes of saving or enhancing patients’ lives. It’s a “race to the finish” in some cases, and the quicker a company can get its product to patients, the better. Sponsored by: Paysign Download the whitepaper for a solution designed to connect manufacturers, pharmacists, and patients. In this special guide, you will learn not just about the law but about the portal platform designed to change the entire process for all. Sponsored by: Cardinal Health 3PL Services Identifying opportunities to simplify channel strategies and business processes for biopharma companies, their customers and patients. Sponsored by: Catalent In a BioPharma Dive industry survey, planning and forecasting were identified as top concerns for trial sponsors. In response to this need, the CSM team at Catalent has developed a methodology for identifying, evaluating, and proactively managing the inherent risks involved in clinical trial supply chain management. Sponsored by: Catalent Learn about a real-world example of how clinical supply management expertise was applied to overcome inventory challenges for a complex, global study. Sponsored by: Catalent Whether a study is simple or highly complex, forecasting and simulation reports serve as data driven communication tools to help minimize risks and keep the study on track. Learn more about forecasting solutions for informed decision making and supporting contingency planning for clinical study. Sponsored by: Catalent Learn how to drive excellence within the forecasting process and utilize forecasting throughout the clinical study to better plan clinical supply budgets and project timelines. Explore how to identify potential supply-related issues before they can negatively impact your study. | 
.jpg)
